natgillin/translations-raw huggingface dataset:
Patients treated with immunosuppressants, including Mycophenolate mofetil Teva, are at increased risk for opportunistic infections (bacterial, fungal, viral and protozoal), fatal infections and sepsis (see section 4.8).
Bolniki, ki se zdravijo z imunosupresivi, vključno z zdravilom Mofetilmikofenolat Teva, imajo povečano tveganje za oportunistične okužbe (bakterijske, glivične, virusne in protozojske), smrtne okužbe in sepso (glejte poglavje 4.8).
These data support extrapolation of this finding to all antacids because the reduction in exposure when mycophenolate mofetil was co- administered with magnesium and aluminium hydroxides is considerably less than when mycophenolate mofetil was co-administered with PPIs.
Ti podatki podpirajo ekstrapolacijo teh ugotovitev na vse antacide, saj je zmanjšanje izpostavljenosti, kadar je zdravilo Mofetilmikofenolat Teva sočasno uporabljeno z magnezijevimi in aluminijevi hidroksidi, občutno manjše v primerjavi s sočasno uporabo zdravila Mofetilmikofenolat Teva in zaviralcev protonske črpalke.
• Facial malformations such as cleft lip, cleft palate, micrognathia and hypertelorism of the orbits;
• malformacije obraza, kot so razcep ustnice, razcep neba, mikrognatija in orbitalni hipertelorizem,
These changes may suggest a ‘left shift' in the maturity of neutrophils in haematological investigations, which may be mistakenly interpreted as a sign of infection in immunosuppressed patients such as those that receive Mycophenolate mofetil Teva.
Te spremembe lahko pri preiskavah krvi predstavljajo ‘premik v levo' pri zorenju nevtrofilcev, kar se lahko pri imunosupresiranih bolnikih, kot so ti, ki prejemajo zdravilo
• You were born with one of the following rare conditions that make pregnancy impossible: the XY genotype, Turner`s syndrome or uterine agenesis.
- Če ste se rodili z enim eno od naslednjih redkih stanj, zaradi katerih nosečnost ni mogoča: genotip XY,
Mycophenolate mofetil Teva is used in children and adolescents (aged 2 to 18) to prevent a body rejecting a transplanted kidney.
Zdravilo Mofetilmikofenolat Teva se uporablja pri otrocih in mladostnikih (starih od 2 do 18 let) za preprečevanje zavrnitve presajene ledvice.
Mycophenolate mofetil Teva capsules should only be prescribed to patients with a body surface area of at least 1.25 m2.
Kapsule zdravila Mofetilmikofenolat Teva lahko predpišemo samo bolnikom, katerih telesna površina je večja od 1,25 m2.
• high level of cholesterol and/or lipids in the blood
• visoka raven sladkorja v krvi • visoka raven holesterola in/ali lipidov v krvi
Mycophenolate mofetil Teva has not been shown to impair your ability to drive or operate machines.
Za zdravilo Mofetilmikofenolat Teva ni bilo pokazano, da vpliva na sposobnost za upravljanje vozil ali strojev.
Before starting Mycophenolate mofetil Teva treatment, women of childbearing potential must have two negative serum or urine pregnancy tests with a sensitivity of at least 25 mIU/mL in order to exclude unintended exposure of the embryo to mycophenolate.
Da izključimo nenamerno izpostavljenost zarodka mofetilmikofenolatu, morajo bolnice v rodni dobi pred začetkom zdravljenja z zdravilom Mofetilmikofenolat Teva opraviti dva serumska ali urinska testa nosečnosti z občutljivostjo najmanj 25 mi.e./ml, ki morata biti negativna.
Patients with a body surface area of 1.25 to 1.5 m2 may be prescribed Mycophenolate mofetil Teva capsules at a dose of 750 mg twice daily (1.5 g daily dose).
Bolnikom s telesno površino med 1,25 in 1,5 m2 predpišemo kapsule zdravila Mofetilmikofenolat Teva v odmerku 750 mg dvakrat na dan (dnevni odmerek 1,5 g).
What Mycophenolate mofetil Teva is and what it is used for What you need to know before you take Mycophenolate mofetil Teva How to take Mycophenolate mofetil Teva Possible side effects
Kaj je zdravilo Mofetilmikofenolat Teva in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Mofetilmikofenolat Teva Kako jemati zdravilo Mofetilmikofenolat Teva
Mycophenolate mofetil Teva is indicated in combination with ciclosporin and corticosteroids for the prophylaxis of acute transplant rejection in patients receiving allogeneic renal, cardiac or hepatic transplants.
Zdravilo Mofetilmikofenolat Teva je indicirano skupaj s ciklosporinom in kortikosteroidi za preprečevanje akutnih zavrnitvenih reakcij pri bolnikih z alogenim ledvičnim, srčnim ali jetrnim presadkom.
Patients receiving Mycophenolate mofetil Teva should be monitored for neutropenia, which may be related to Mycophenolate mofetil Teva itself, concomitant medicinal products, viral infections, or some combination of these causes.
Bolnike, ki prejemajo zdravilo Mofetilmikofenolat Teva, je treba skrbno nadzorovati zaradi nevtropenije, ki je lahko posledica jemanja zdravila Mofetilmikofenolat Teva, sočasno uporabljenih zdravil, virusnih okužb ali nekaterih kombinacij teh vzrokov.
Patients should be instructed to consult their physician immediately should pregnancy occur.
Bolnicam je treba svetovati, naj v primeru zanositve takoj obvestijo svojega zdravnika.
Hypersensitivity reactions to Mycophenolate mofetil Teva have been observed (see section 4.8).
Opazili so preobčutljivostne reakcije na mofetilmikofenolat (glejte poglavje 4.8).
Mycophenolate is a powerful human teratogen.
Teratogeni učinki Mofetilmikofenolat je močan humani teratogen.
• For 6°weeks after you stop taking Mycophenolate mofetil Teva.
- 6 tednov po prenehanju jemanja zdravila Mofetilmikofenolat Teva.
Mycophenolate mofetil Teva should not be given to patients with hypersensitivity to mycophenolate mofetil, mycophenolic acid or to any of the excipients listed in section 6.1.
Zdravila Mofetilmikofenolat Teva ne smemo uporabljati pri bolnikih s preobčutljivostjo za mofetilmikofenolat, mikofenolno kislino ali katero koli pomožno snov, navedeno v poglavju 6.1.
Pharmacokinetic behaviour of mycophenolate mofetil in the elderly (≥°65 years) has not been formally evaluated.
Starejši bolniki Farmakokinetičnih parametrov mofetilmikofenolata pri starejših bolnikih (starih 65 let ali več) niso proučevali.
Caution should be used with medicinal products that interfere with enterohepatic circulation because of their potential to reduce the efficacy of mycophenolate mofetil.
Pri uporabi zdravil, ki vplivajo na enterohepatični obtok, je potrebna previdnost, saj lahko zmanjšajo učinkovitost mofetilmikofenolata.
How to store Mycophenolate mofetil Teva Contents of the pack and other information
Shranjevanje zdravila Mofetilmikofenolat Teva Vsebina pakiranja in dodatne informacije
Adverse reactions, probably or possibly related to mycophenolate mofetil, reported in ≥1/10 and in
Drugi neželeni učinki Neželeni učinki, ki so verjetno ali možno povezani z mofetilmikofenolatom in so se pojavili pri ≥1/10 in pri
Contents of the pack and other information What Mycophenolate mofetil Teva contains
Vsebina pakiranja in dodatne informacije Kaj vsebuje zdravilo Mofetilmikofenolat Teva
In the kidney MPA and its metabolites potently interact with renal organic anion transporters.
ledvicah pride do močne interakcije mikofenolne kisline in njenih metabolitov z ledvičnimi organskimi anionskimi prenašalci.
If neutropenia develops (absolute neutrophil count <°1.3°x 103/°µl) it may be appropriate to interrupt or discontinue Mycophenolate mofetil Teva.
Če se pojavi nevtropenija (absolutno število nevtrofilcev < 1,3 x 103/µl), moramo odmerke zdravila Mofetilmikofenolat Teva zmanjšati ali zdravljenje prekiniti.
Mycophenolate mofetil Teva should not be used during pregnancy unless there is no suitable alternative treatment to prevent transplant rejection (see section 4.6).
Zdravila Mofetilmikofenolat Teva ne smemo uporabljati med nosečnostjo, razen če ni na voljo primernega alternativnega zdravljenja za preprečitev zavrnitve presadka (glejte poglavje 4.6).
• Abnormalities of the ear (e.g. abnormally formed or absent external ear), external auditory canal atresia (middle ear);
• nenormalna ušesa (npr. nenormalna oblika ali manjkajoče zunanje/srednje uho), atrezija zunanjega sluhovoda (srednjega ušesa),
Mycophenolate mofetil Teva should not be used in children and adolescents (aged 2 to 18) for heart or liver transplantation.
Zdravila Mofetilmikofenolat Teva se ne sme uporabljati pri otrocih in mladostnikih (starih od 2 do 18 let) za preprečevanje zavrnitve presajenega srca ali jeter.
In teratology studies in rats and rabbits, foetal resorptions and malformations occurred in rats at 6 mg/kg/day (including anophthalmia, agnathia, and hydrocephaly) and in rabbits at 90 mg/kg/day (including cardiovascular and renal anomalies, such as ectopia cordis and ectopic kidneys, and diaphragmatic and umbilical hernia), in the absence of maternal toxicity.
6 mg/kg/dan pri podganah (vključno z anoftalmijo, agnatijo in hidrocefalijo) ter pri odmerkih 90 mg/kg/dan pri kuncih (vključno s kardiovaskularnimi motnjami in motnjami delovanja ledvic, kot so ektopija srca in ledvic ter preponska in popkovna kila), pri materah pa škodljivih učinkov ni bilo.
Oral Mycophenolate mofetil Teva should be initiated within 72°hours following transplantation.
Zdravilo Mofetilmikofenolat Teva damo uvodoma peroralno v 72 urah po presaditvi.
Do not crush the tablets.
Tablet ne smete lomiti ali zmečkati.
• Your womb (uterus) has been removed by surgery (hysterectomy).
- Če so vam z operacijo odstranili maternico (histerektomija).
Therefore Mycophenolate mofetil Teva is contraindicated in pregnancy unless there are no suitable alternative treatments to prevent transplant rejection.
Zato je zdravilo Mofetilmikofenolat Teva med nosečnostjo kontraindicirano, razen če za preprečitev zavrnitve presadka ni na voljo primernih alternativnih zdravljenj.
The first dose will be given within 5 days following the transplant operation.
Odrasli Prvi odmerek boste prejeli v 5 dneh po presaditvenem posegu.
Other medicines and Mycophenolate mofetil Teva
Druga zdravila in zdravilo Mofetilmikofenolat Teva
Mycophenolate mofetil Teva is contraindicated during pregnancy unless there is no suitable alternative treatment to prevent transplant rejection.
Zdravilo Mofetilmikofenolat Teva je med nosečnostjo kontraindicirano, razen če za preprečitev zavrnitve presadka ni na voljo primernega alternativnega zdravljenja.
• serious disease of the kidney (BK virus associated nephropathy)
• resna bolezen ledvic (nefropatija, povezana z virusom BK)
As a precaution you or your female partner are recommended to use reliable contraception during treatment and for 90°days after you stop taking Mycophenolate mofetil Teva.
Kot previdnostni ukrep je za vas ali vašo partnerko priporočljivo, da med zdravljenjem in 90 dni po končanem zdravljenju uporabljate/uporablja zanesljivo obliko kontracepcije.
In hepatic transplant patients initiated on mycophenolate mofetil and tacrolimus, the AUC and Cmax of MPA, the active metabolite of mycophenolate mofetil, were not significantly affected by coadministration with tacrolimus.
Takrolimus Pri bolnikih z jetrnim presadkom, pri katerih so uvedli mofetilmikofenolat in takrolimus, sprememba AUC in cmax mikofenolne kisline, aktivnega presnovka mofetilmikofenolata, zaradi sočasnega dajanja takrolimusa ni bila pomembna.
Adverse reactions, probably or possibly related to mycophenolate mofetil, reported in patients treated with mycophenolate mofetil in renal, cardiac and hepatic clinical trials when used in combination with ciclosporin and corticosteroids
Neželeni učinki, verjetno ali možno povezani z mofetilmikofenolatom, ki so se pojavili pri bolnikih, zdravljenih z mofetilmikofenolatom v kombinaciji s ciklosporinom in kortikosteroidi pri kliničnih preskušanjih bolnikov z ledvičnim, srčnim ali jetrnim presadkom.
Decreased MPA exposure has been observed when antacids, such as magnesium and aluminium hydroxides, and PPIs, including lansoprazole and pantoprazole, were administered with mycophenolate mofetil.
Pri dajanju antacidov, kot so magnezijevi in aluminijevi hidroksidi, in zaviralcev protonske črpalke, vključno z lanzoprazolom in pantroprazolom, skupaj z zdravilom Mofetilmikofenolat Teva, so opazili zmanjšano izpostavljenost mikofenolni kislini.
Mycophenolate mofetil Teva 500 mg film-coated tablets are available in PVC/PVdC-aluminium blisters in pack sizes of 50 or 150 or 50 x 1 tablets per carton.
Zdravilo Mofetilmikofenolat Teva 500 mg filmsko obložene tablete je na voljo v PVC/PVdC aluminijastem pretisnem omotu, v pakiranjih po 50 ali 150 ali 50 x 1 tableta v škatli
Caution should be exercised when switching combination therapy from regimens containing immunosuppressants, which interfere with MPA enterohepatic recirculation, e.g. ciclosporin, to others devoid of this effect, e.g. tacrolimus, sirolimus, belatacept, or vice versa, as this might result in changes of MPA exposure.
Pri prehodu s kombiniranega zdravljenja s shemo z imunosupresivi, ki ovirajo enterohepatični obtok mikofenolne kisline (npr. ciklosporin) na druge, ki nimajo takega učinka (npr. takrolimus, sirolimus, belatacept), ali obratno, je potrebna previdnost, saj to lahko vodi k spremembam izpostavljenosti mikofenolni kislini.
Mycophenolate mofetil Teva treatment should not be initiated in women of child bearing potential without providing a pregnancy test result to rule out unintended use in pregnancy (see section 4.6).
Zdravljenja z zdravilom Mofetilmikofenolat Teva ne smemo uvesti pri bolnicah v rodni dobi, ki ne zagotovijo izvida testa nosečnosti, da izključimo nenamerno uporabo zdravila med nosečnostjo (glejte poglavje 4.6).
Precautions to be taken before handling or administering the medicinal product Because mycophenolate mofetil has demonstrated teratogenic effects in rats and rabbits, Mycophenolate mofetil Teva tablets should not be crushed.
Previdnostni ukrepi, potrebni pred ravnanjem z zdravilom ali dajanjem zdravila Ker ima mofetilmikofenolat dokazane teratogene učinke pri podganah in kuncih, filmsko obloženih tablet zdravila Mofetilmikofenolat Teva ne smemo drobiti.
There have been published reports of bronchiectasis in adults and children who received mycophenolate mofetil in combination with other immunosuppressants.
Objavljeni so bili primeri bronhiektaze pri odraslih in otrocih, ki so prejeli mofetilmikofenolat v kombinaciji z drugimi imunosupresivi.
No substantial alteration of MPA pharmacokinetics is anticipated and mycophenolate mofetil dose adjustment is not required.
Znatnih sprememb v farmakokinetiki mikofenolne kisline ni pričakovati, zato prilagajanje odmerkov zdravila Mofetilmikofenolat Teva ni potrebno.
Gingival hyperplasia (≥1/100 to <1/10), colitis including cytomegalovirus colitis (≥1/100 to <1/10),
Prebavila Gingivalna hiperplazija (≥ 1/100 do < 1/10), kolitis, vključno s kolitisom, ki ga povzroča citomegalovirus
Congenital malformations have been observed post-marketing in children of patients exposed to mycophenolate mofetil in combination with other immunosuppressants, see section 4.6.
Po prihodu zdravila na trg so pri otrocih bolnikov, ki so bili izpostavljeni zdravilu Mofetilmikofenolat Teva v kombinaciji z drugimi imunosupresivi, poročali o kongenitalnih malformacijah; glejte poglavje 4.6.
Do not break or crush them.
Kapsul ne smete lomiti ali zmečkati.
• inflammation of the colon which causes abdominal pain or diarrhoea (sometimes caused by cytomegalovirus), ulcer of the stomach and/or duodenum, inflammation of the stomach,
• vnetje debelega črevesa, ki povzroča bolečine v trebuhu ali drisko (včasih posledica citomegalovirusa),
Mycophenolate mofetil Teva contains sodium
Zdravilo Mofetilmikofenolat Teva vsebuje natrij
However, the following treatment-related adverse events were more frequent in the paediatric population, particularly in children under 6°years of age, when compared to adults: diarrhoea, sepsis, leucopenia, anaemia and infection.
zlasti pri otrocih, mlajših od 6 let: driska, sepsa, levkopenija, anemija in okužba.
Capsule content Pregelatinised starch (maize) Povidone K-30
Kapsula vsebuje predgeliran koruzni škrob povidon K-30 premrežen natrijev karmelozat magnezijev stearat
Hypogammaglobulinaemia has been reported in patients receiving mycophenolate mofetil in combination with other immunosuppressants (frequency not known).
Bolezni imunskega sistema O hipogamaglobulinemiji so poročali pri bolnikih, ki so mofetilmikofenolat prejemali v kombinaciji z drugimi imunosupresivi (pogostnost ni poznana).
Patients receiving immunosuppressive regimens involving combinations of medicinal products, including Mycophenolate mofetil Teva, are at increased risk of developing lymphomas and other malignancies, particularly of the skin (see section 4.8).
Bolniki, ki prejemajo kombinacije imunosupresivnih zdravil, vključno z zdravilom Mofetilmikofenolat Teva , so izpostavljeni povečanem tveganju nastanka limfomov in drugih malignih sprememb, zlasti kožnih (glejte poglavje 4.8).
PRCA may resolve with dose reduction or cessation of Mycophenolate mofetil Teva therapy.
PRCA je lahko reverzibilna z zmanjšanjem odmerka ali s prekinitvijo zdravljenja z zdravilom Mofetilmikofenolat Teva.
Changes to Mycophenolate mofetil Teva therapy should only be undertaken under appropriate supervision in transplant recipients in order to minimise the risk of graft rejection (see section 4.8).
Pri bolnikih s presadki se zaradi zmanjšanja tveganja za zavrnitev presadka spremembe v zdravljenju z zdravilom Mofetilmikofenolat Teva lahko uvaja le pod ustreznim nadzorom (glejte poglavje 4.8).
Therefore women with childbearing potential must use at least one form of reliable contraception (see section 4.3) before starting Mycophenolate mofetil Teva therapy, during therapy, and for six weeks after stopping the therapy, unless abstinence is the chosen method of contraception.
Zato morajo ženske v rodni dobi pred začetkom zdravljenja, med zdravljenjem in šest tednov po končanem zdravljenju z zdravilom Mofetilmikofenolat Teva uporabljati vsaj eno zanesljivo obliko kontracepcije (glejte poglavje 4.3), razen če niso izbrale metode vzdržnosti.
Mycophenolate mofetil Teva 250 mg hard capsules are available in PVC/PVdC-aluminium blisters in pack sizes of 100 or 300 or 100 x 1 capsules per carton.
Zdravilo Mofetilmikofenolat Teva 250 mg trde kapsule je na voljo v prozornem PVC/PVdC aluminijastem pretisnem omotu, v pakiranjih po 100 ali 300 ali 100 x 1 kapsula v škatli.
The following undesirable effects cover adverse reactions from post-marketing experience The types of adverse reactions reported during post-marketing with mycophenolate mofetil are similar to those seen in the controlled renal, cardiac and hepatic transplant studies.
Neželeni učinki, ki so se pojavili v postmarketinških raziskavah zdravljenja z mofetilmikofenolatom, so podobni neželenim učinkom v nadzorovanih raziskavah bolnikov z ledvičnim, srčnim in jetrnim presadkom.
Note: 501 (2°g mycophenolate mofetil daily), 289 (3°g mycophenolate mofetil daily) and 277 (2°g intravenous/3°g oral mycophenolate mofetil daily) patients were treated in Phase III studies for the prevention of rejection in renal, cardiac and hepatic transplantation, respectively.
(2 g mofetilmikofenolata na dan), 289 (3 g mofetilmikofenolata na dan) in 277 (2 g i.v./3 g peroralne oblike mofetilmikofenolata na dan) bolnikov.
Do not stop taking Mycophenolate mofetil Teva because you feel better.
Če ste prenehali jemati zdravilo Mofetilmikofenolat Teva Zdravljenja z zdravilom Mofetilmikofenolat Teva ne prekinjajte, ker se počutite bolje.
Mycophenolate mofetil Teva is a medicine that is used to suppress immune activity.
Zdravilo Mofetilmikofenolat Teva spada v skupino zdravil, znano kot zdravila za zaviranje imunske odzivnosti.
It is recommended that mycophenolate mofetil should not be administered concomitantly with azathioprine because such concomitant administration has not been studied.
Ne priporočamo sočasnega dajanja zdravila Mofetilmikofenolat Teva in azatioprina, ker kombiniranega jemanja teh zdravil niso proučevali.
• accumulation of fluid in the lung, shortness of breath, cough
• krvnih žil kopičenje tekočine v pljučih, kratka sapa, kašelj
Mycophenolate mofetil Teva should not be given to women of childbearing potential who are not using highly effective contraception (see section 4.6).
Zdravila Mofetilmikofenolat Teva ne smemo uporabljati pri bolnicah v rodni dobi, ki ne uporabljajo zelo učinkovitih kontracepcijskih metod (glejte poglavje 4.6).
Contraception in men taking Mycophenolate mofetil Teva
Kontracepcija pri moških, ki jemljejo zdravilo Mofetilmikofenolat Teva
Decrease in MPA Cmax and AUC0-12h by 30% and 25%, respectively, were observed when mycophenolate mofetil was concomitantly administered with sevelamer without any clinical consequences (i.e. graft rejection).
30 % in AUC0-12h mikofenolne kisline za 25 %, kliničnih posledic (zavrnitve presadka) pa ni bilo.
CsA interferes with MPA enterohepatic recycling, resulting in reduced MPA exposures by 30-50% in renal transplant patients treated with mycophenolate mofetil and CsA compared with patients receiving sirolimus or belatacept and similar doses of mycophenolate mofetil (see also section 4.4).
Ciklosporin A vpliva na enterohepatični obtok mikofenolne kisline in s tem zmanjša izpostavljenost mikofenolni kislini za 30 - 50 % pri bolnikih z ledvičnim presadkom, ki so bili zdravljeni z mofetilmikofenolata in ciklosporinom A, v primerjavi z bolniki, ki so prejemali sirolimus ali belatacept in podobne odmerke mofetilmikofenolata (glejte tudi poglavje 4.4).
Oral Mycophenolate mofetil Teva should be initiated within 5 days following transplantation.
V začetku damo zdravilo Mofetilmikofenolat Teva peroralno v 5 dneh po presaditvi.
Mycophenolate mofetil Teva should not be given to women who are breastfeeding (see section 4.6).
Zdravila Mofetilmikofenolat Teva ne smemo uporabljati pri bolnicah, ki dojijo (glejte poglavje 4.6).
If you answer yes to any of the following questions talk to your doctor before you start to take Mycophenolate mofetil Teva:
Če na katero od spodaj naštetih vprašanj odgovorite pritrdilno, se pred jemanjem zdravila Mofetilmikofenolat
Cases of pure red cell aplasia (PRCA) have been reported in patients treated with mycophenolate mofetil (see section 4.4).
Bolezni krvi in limfatičnega sistema Pri zdravljenju z mofetilmikofenolatom so poročali o primerih čiste aplazije rdečih krvnih celic (PRCA) (glejte poglavje 4.4).
• The need to avoid foetal exposure: Contraceptive requirements for patients of reproductive potential prior to, during and after treatment with mycophenolate mofetil.
• Nujnost izogibanja izpostavljenosti ploda Opisane bodo zahteve za kontracepcijo za bolnike in bolnice v rodni dobi pred, med in po zdravljenju z mofetilmikofenolatom, zahteve za kontracepcijo za spolno aktivne bolnike (vključno z vazektomiziranimi) in bolnice v rodni dobi ter potrebo po kontracepciji pred, med in po zdravljenju z mofetilmikofenolatom,
When comparing rates of transplant rejection or rates of graft loss between mycophenolate mofetil patients taking PPIs vs. mycophenolate mofetil patients not taking PPIs, no significant differences were seen.
Pri primerjavi deležev zavrnitve presadka ali deležev izgube presadka med bolniki, ki so jemali zdravilo Mofetilmikofenolat Teva in zaviralce protonske črpalke ter bolniki, ki so jemali zdravilo Mofetilmikofenolat Teva in niso jemali zaviralcev protonske črpalke, niso opazili značilnih razlik.
Mycophenolate mofetil Teva 250 mg Capsules
Mofetilmikofenolat Teva 250 mg kapsule
values similar to those seen in adult renal transplant patients receiving mycophenolate mofetil at a dose of 1°g BID in the early and late post-transplant period.
18 let), ki so prejemali 600 mg/m2 mofetilmikofenolata peroralno dvakrat na dan. Ti odmerki so dali podobne vrednosti AUC mikofenolne kisline kot pri odraslih bolnikih z ledvičnim presadkom, ki so prejemali mofetilmikofenolat v odmerku 1 g dvakrat na dan v začetnem in poznejšem obdobju po presaditvi.
It is recommended that patients who develop persistent pulmonary symptoms, such as cough and dyspnoea, are investigated.
pri katerih pulmonalni simptomi, kot sta kašelj in dispneja, vztrajajo, je priporočljivo pregledati.